Clinical trials: Allogenic Disease
Hematologic Malignancies
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
The researchers are doing this study to compare 2 different GVHD prevention (prophylaxis) approaches. The researchers will see which approach is good or more effective at preventing chronic GVHD until 1 year after allogeneic…
- Trial name
- NCT07359859
- Testing
- Cyclophosphamide, Mycophenolate Mofetil, Ruxolitinib
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bronchiectasis
Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis
To demonstrate the safety of bone marrow-derived allogeneic human Mesenchymal Stem Cells (hMSCs) in patients with bronchiectasis receiving standard of care therapy, and to explore treatment efficacy
- Trial name
- CELEB (NCT02625246)
- Testing
- hMSCs
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Marilyn Glassberg
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
NK Cells in Cord Blood Transplantation
This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Trial name
- NCT01619761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML)
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.
- Conditions
- Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Hodgkin Lymphoma
- Trial name
- NCT03615105
- Testing
- Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Osteoarthritis, Knee, Articular Cartilage Defects of the Knee
Subchondral Drilling Diameter During CARTISTEM Implantation for Knee Cartilage Defects
This prospective, randomized study at Severance Hospital compares two subchondral drilling techniques during CARTISTEM implantation for symptomatic medial-compartment knee articular cartilage defects.
- Trial name
- NCT07881445
- Testing
- 2-mm subchondral drilling, Sequential 4-mm and 2-mm subchondral drilling
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Stem Cell Transplantation, Leukemia
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
The goal of this clinical research study is to learn if Vidaza (azacitidine) when given to patients with CML after an donor stem cell transplant will increase the likelihood of achieving a complete remission of CML.
- Trial name
- NCT00813124
- Testing
- Fludarabine, Busulfan, Thymoglobulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Septic Shock
Pentaglobin in CRE and PA Neutropenic Infections
To demonstrate that the early addition of Pentaglobin to the best available antimicrobial therapy is able to reduce mortality and improve survival in neutropenic febrile acute leukemia or allo- Hematopoietic stem cell…
- Trial name
- PENTALLO (NCT03494959)
- Testing
- Pentaglobin
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Acute Myeloid Leukemia
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
This phase Ib/II trial tests the safety of tagraxofusp when given with or without azacitidine in patients with acute myeloid leukemia in remission with measurable residual disease who will undergo allogeneic hematopoietic cell…
- Trial name
- NCT05720988
- Testing
- Azacitidine, Tagraxofusp-erzs
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Hematologic Malignancies, Graft vs Host Disease
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
The proposed research study is to test the drug vorinostat, in a new use as an additional medication, with other standard treatments for the prevention of severe acute graft versus host disease (GVHD).
- Trial name
- NCT00810602
- Testing
- reduced intensity, related donor stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis)
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Pavan Reddy, MD
Acute Lymphoblastic Leukemias, Acute Myelocytic Leukemia
Stem Cell Transplantation for Patients With Hematologic Malignancies
Childhood leukemias which cannot be cured by chemotherapy alone may be effectively treated by allogeneic bone marrow transplantation.
- Conditions
- Acute Lymphoblastic Leukemias, Acute Myelocytic Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia
- Trial name
- NCT00152139
- Testing
- Allogeneic Stem Cell Transplantation, Chemotherapy and antibodies
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)
Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure.
- Conditions
- Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma
- Trial name
- FluBuBe (NCT04942730)
- Testing
- Fludarabine, Bendamustine Hydrochloride, Busulfan
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Hematological Neoplasms, Hematopoietic Stem Cell Transplantation
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
- Trial name
- NCT00582894
- Testing
- Busulfex, Fludarabine, ALemtuzumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Oklahoma
Rectal Fistula
Mesenchymal Stem Cells (MSCs) for Perianal Fistula
OSSM-001 will be evaluated in a double blind, randomized phase I safety study of a single injection of 100 and 300 million bone marrow derived MSCs in 16 patients with refractory perianal fistulas in the setting of Crohn's…
- Trial name
- NCT05407766
- Testing
- OSSM-001
- Sponsor
- Ossium Health, Inc.
Hematologic Disease
Pharmaco-economic Study of a New Medical Device Performed From the Perspective of the Hospital
The purpose of the study is to determine whether the use of mouthwashes Caphosol ™ in addition to standard oral care (strategy A) is cost-effective in the prevention and treatment of severe mucositis in adult patients with auto…
- Trial name
- Caphosol (NCT01426295)
- Testing
- Caphosol, Bicarbonate de sodium
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Nantes University Hospital
Covid19
Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19
This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic…
- Trial name
- CoronaStem1 (NCT04486001)
- Testing
- PSC-04
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sorrento Therapeutics, Inc.
Sepsis, Septic Shock
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
Sepsis remains the leading cause of ICU admission in neutropenic patients. This condition remains associated with a high morbidity and mortality, with hospital mortality of 60% when vasopressors are required.
- Conditions
- Sepsis, Septic Shock, Hematologic Malignancy, Tumor
- Trial name
- NCT05443854
- Testing
- Aminoglycosides intervention, Lack of protective isolation intervention, No systematic aminoglycosides intervention - standard arm
- Volunteers
- 340 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia
Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory AML.
- Trial name
- NCT06197672
- Testing
- CD4CAR
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Huda Salman
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
Large B-cell Lymphoma
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have…
- Trial name
- ALPHA3 (NCT06500273)
- Testing
- cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide
- Where
- 86 sites in United States, Australia and 2 more
- Volunteers
- 250 people
- Sponsor
- Allogene Therapeutics
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or…
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03670966
- Testing
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.